Quantum BioPharma Ltd. Total Assets
Quantum BioPharma Ltd. total assets. Based on the latest financial reports, Quantum BioPharma Ltd. (QNTM) holds total assets worth $14.37 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see QNTM company net worth for the company's overall valuation and market capitalisation.
Total Assets of Quantum BioPharma Ltd. (2015–2025)
Total assets of Quantum BioPharma Ltd. from 2015 to 2025. This chart illustrates how Quantum BioPharma Ltd.'s total assets have evolved over time, based on quarterly financial data. See today's stock price for Quantum BioPharma Ltd. for real-time trading data and today's change.
Quantum BioPharma Ltd. - Asset Composition Analysis
Quantum BioPharma Ltd. Total Assets Breakdown (December 2025)
Quantum BioPharma Ltd. total assets breakdown as of December 2025. Quantum BioPharma Ltd.'s total assets of $14.37 Million consist of 58.1% current assets and 42.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.1% |
| Accounts Receivable | $230.63K | 2.1% |
| Inventory | $52.04K | 0.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.50 Million | 40.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Quantum BioPharma Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore QNTM current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Quantum BioPharma Ltd.'s current assets represent 58.1% of total assets in 2025, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 17.1% of total assets in 2025, up from 0.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 40.4% of total assets.
Quantum BioPharma Ltd. Competitors by Total Assets
Key competitors of Quantum BioPharma Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Quantum BioPharma Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.20 | 0.78 | 5.89 |
| Quick Ratio | 1.19 | 0.77 | 5.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.66 Million | $-2.91 Million | $41.40 Million |
Quantum BioPharma Ltd. - Advanced Valuation Insights
This section examines the relationship between Quantum BioPharma Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 1.28 |
| Asset Growth Rate (YoY) | -34.9% |
| Total Assets | $11.14 Million |
| Market Capitalization | $14.21 Million USD |
Valuation Analysis
Above Book Valuation: The market values Quantum BioPharma Ltd.'s assets above their book value (1.28x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Quantum BioPharma Ltd.'s assets decreased by 34.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Quantum BioPharma Ltd. (2015–2025)
The table below shows the annual total assets of Quantum BioPharma Ltd. from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $11.14 Million | -34.92% |
| 2024-12-31 | $17.12 Million | -2.03% |
| 2023-12-31 | $17.47 Million | -54.51% |
| 2022-12-31 | $38.41 Million | -38.99% |
| 2021-12-31 | $62.96 Million | +50.03% |
| 2020-12-31 | $41.97 Million | -2.89% |
| 2019-12-31 | $43.22 Million | +11.53% |
| 2018-12-31 | $38.75 Million | +256.19% |
| 2017-12-31 | $10.88 Million | +152323.76% |
| 2016-12-31 | $7.14K | +230.42% |
| 2015-12-31 | $2.16K | -- |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more